[{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Onabotulinumtoxin A","moa":"ACh release","graph1":"Dermatology","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Allergan Aesthetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Allergan Aesthetics \/ Inapplicable"},{"orgOrder":0,"company":"Perrigo Company plc","sponsor":"Sol-Gel Technologies","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Benzoyl Peroxide","moa":"Keratinocyte","graph1":"Dermatology","graph2":"Phase III","graph3":"Perrigo Company plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Perrigo Company plc \/ Sol-Gel Technologies","highestDevelopmentStatusID":"10","companyTruncated":"Perrigo Company plc \/ Sol-Gel Technologies"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Cosmo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cosmo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Nogra Pharma","sponsor":"Torii Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"NAC-GED-0507","moa":"PPA-gamma receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Nogra Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Nogra Pharma \/ Torii Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Nogra Pharma \/ Torii Pharmaceutical"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"TrenibotulinumtoxinE","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Allergan Aesthetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Allergan Aesthetics \/ Inapplicable"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Details : AGN-151586 (trenibotulinumtoxinE) is a first-in-class, short-acting neurotoxin, which is investigated for the treatment of Glabellar Lines. If approved, BoNT/E will be the first neurotoxin of its kind available to patients.

                          Product Name : AGN-151586

                          Product Type : Other Large Molecule

                          Upfront Cash : Inapplicable

                          October 24, 2023

                          Lead Product(s) : TrenibotulinumtoxinE

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Abbvie CB

                          02

                          Details : Botox Cosmetic (onabotulinumtoxinA) is first and only product of its kind that is approved by U.S. FDA to treat three areas, temporarily improving the appearance of moderate to severe forehead lines, glabellar lines and crow's feet in adults.

                          Product Name : Botox

                          Product Type : Other Large Molecule

                          Upfront Cash : Inapplicable

                          September 18, 2023

                          Lead Product(s) : Onabotulinumtoxin A

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Abbvie CB

                          03

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : CB-03-01 (clascoterone) solution is an androgen receptor inhibitor which is currently being evaluated for the treatment of patients with androgenetic alopecia.

                          Product Name : Winlevi

                          Product Type : Steroid

                          Upfront Cash : Inapplicable

                          June 29, 2023

                          Lead Product(s) : Clascoterone

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Under the agreement, Torii Pharmaceuticals will gain exclusive development and commercialisation rights for NAC-GED-0507 in Japan for the treatment of acne vulgaris. NAC-GED-0507 is an IP protected, Phase III-ready, small molecule selective modulator of ...

                          Product Name : NAC-GED-0507

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          January 26, 2023

                          Lead Product(s) : NAC-GED-0507

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Torii Pharmaceutical

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          05

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Consistent with Sol-Gel’s prior agreements, Perrigo will seek regulatory approval with the U.S. FDA for these generic product candidates. If approved by the FDA, Perrigo will lead the commercialization efforts for the generic product candidates in the ...

                          Product Name : Epsolay

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          June 29, 2020

                          Lead Product(s) : Benzoyl Peroxide

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Sol-Gel Technologies

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank